A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vildagliptin (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics
Acronyms VIVIDD Study
Sponsors Novartis Pharmaceuticals

Most Recent Events

13 Aug 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
03 May 2012 Planned end date changed from 1 Jan 2013 to 1 Aug 2012 as reported by ClinicalTrials.gov.
16 Nov 2011 Actual initiation date changed from 4 May 2009 to 27 April 2009 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight